Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer.

Manabe Y, Shibamoto Y, Sugie C, Baba F, Ayakawa S, Nagai A, Takemoto S, Hayashi A, Kawai N, Takeuchi M, Ishikura S, Kohri K, Yanagi T.

J Radiat Res. 2014 May;55(3):494-501. doi: 10.1093/jrr/rrt124. Epub 2013 Oct 17.

2.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L.

Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.

PMID:
25656287
3.

Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer.

Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J, Kovarik J.

Strahlenther Onkol. 2015 Apr;191(4):338-46. doi: 10.1007/s00066-014-0806-y. Epub 2015 Jan 15.

PMID:
25589224
4.

Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.

Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, Shimizu S, Nonomura K, Koyanagi T, Miyasaka K.

Cancer J. 2003 Jul-Aug;9(4):268-76.

PMID:
12967137
5.

Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.

Dolezel M, Odrazka K, Vaculikova M, Vanasek J, Sefrova J, Paluska P, Zouhar M, Jansa J, Macingova Z, Jarosova L, Brodak M, Moravek P, Hartmann I.

Strahlenther Onkol. 2010 Apr;186(4):197-202. doi: 10.1007/s00066-010-2065-x. Epub 2010 Mar 26.

PMID:
20354663
6.
7.

Analysis of late toxicity associated with external beam radiation therapy for prostate cancer with uniform setting of classical 4-field 70 Gy in 35 fractions: a survey study by the Osaka Urological Tumor Radiotherapy Study Group.

Yoshioka Y, Suzuki O, Nishimura K, Inoue H, Hara T, Yoshida K, Imai A, Tsujimura A, Nonomura N, Ogawa K.

J Radiat Res. 2013 Jan;54(1):113-25. doi: 10.1093/jrr/rrs083. Epub 2012 Sep 17.

8.

Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT.

Guckenberger M, Lawrenz I, Flentje M.

Strahlenther Onkol. 2014 Jan;190(1):48-53. doi: 10.1007/s00066-013-0443-x. Epub 2013 Nov 8.

PMID:
24196279
9.

Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.

Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.

Eur Urol. 2011 Dec;60(6):1142-8. doi: 10.1016/j.eururo.2011.08.006. Epub 2011 Aug 12.

PMID:
21855208
10.

Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.

Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):686-92. doi: 10.1016/j.ijrobp.2012.05.023. Epub 2012 Jul 12.

PMID:
22795805
11.

Hypofractionated helical tomotherapy using 2.5-2.6 Gy daily fractions for localized prostate cancer.

Lopez Guerra JL, Isa N, Matute R, Russo M, Puebla F, Kim MM, Sanchez-Reyes A, Beltran C, Jaen J, Bourgier C, Marsiglia H.

Clin Transl Oncol. 2013 Apr;15(4):271-7. doi: 10.1007/s12094-012-0907-y. Epub 2012 Jul 24.

PMID:
22855189
12.

Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.

Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1463-8. Epub 2005 Sep 19.

PMID:
16169683
13.

Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.

Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e415-21. doi: 10.1016/j.ijrobp.2011.01.024. Epub 2011 Apr 7.

PMID:
21477939
14.

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. doi: 10.1016/j.ijrobp.2010.09.018. Epub 2010 Dec 14.

15.

Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.

Patel N, Faria S, Cury F, David M, Duclos M, Shenouda G, Ruo R, Souhami L.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):534-9. doi: 10.1016/j.ijrobp.2013.02.010. Epub 2013 Apr 15.

PMID:
23597418
16.

Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.

Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK.

J Urol. 2013 Aug;190(2):521-6. doi: 10.1016/j.juro.2013.02.012. Epub 2013 Feb 13.

PMID:
23415964
17.

Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.

Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR.

Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):904-12.

PMID:
12095556
18.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

19.

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.

Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1013-20. doi: 10.1016/j.ijrobp.2008.12.047. Epub 2009 Apr 20.

PMID:
19386427
20.

High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.

J Urol. 2001 Sep;166(3):876-81. Erratum in: J Urol 2001 Nov;166(5):1839.

PMID:
11490237

Supplemental Content

Support Center